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Tumor-Specific T Cells in Human Merkel Cell
Carcinomas: A Possible Role for Tregs and T-Cell
Exhaustion in Reducing T-Cell Responses
Mitra Dowlatshahi1, Victor Huang1, Ahmed E. Gehad1, Ying Jiang2, Adam Calarese3, Jessica E. Teague1,
Andrew A. Dorosario4, Jingwei Cheng5,6, Paul Nghiem7, Carl F. Schanbacher8, Manisha Thakuria1,
Chrysalyne D. Schmults1, Linda C. Wang9 and Rachael A. Clark1
Merkel cell carcinomas (MCCs) are rare but highly malignant skin cancers associated with a recently described
polyomavirus. MCC tumors were infiltrated by T cells, including effector, central memory, and regulatory T cells.
Infiltrating T cells showed markedly reduced activation as evidenced by reduced expression of CD69 and CD25.
Treatment of MCC tumors in vitro with IL-2 and IL-15 led to T-cell activation, proliferation, enhanced cytokine
production, and loss of viable tumor cells from cultures. Expanded tumor-infiltrating lymphocytes showed TCR
repertoire skewing and upregulation of CD137. MCC tumors implanted into immunodeficient mice failed to grow
unless human T cells in the tumor grafts were depleted with denileukin diftitox, suggesting that tumor-specific
T cells capable of controlling tumor growth were present in MCC. Both CD4þ and CD8þ FOXP3þ regulatory
T cells were frequent in MCC. Fifty percent of nonactivated T cells in MCC-expressed PD-1, a marker of T-cell
exhaustion, and PD-L1 and PD-L2 were expressed by a subset of tumor dendritic cells and macrophages. In
summary, we observed tumor-specific T cells with suppressed activity in MCC tumors. Agents that stimulate T-cell
activity, block regulatory T cell function, or inhibit PD-1 signaling may be effective in the treatment of this highly
malignant skin cancer.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare and highly malignant
neuroendocrine cancer that arises in the skin. MCC has a
mortality rate of 30%, making it a more deadly cancer than
malignant melanoma (Agelli and Clegg, 2003), and incidence
has tripled in the last 20 years (Agelli et al., 2010). MCC is
more frequent in immunosuppressed individuals, and the
recently described Merkel cell polyomavirus (MCPyV) has
been implicated in its etiology (Becker et al., 2008; Feng et al.,
2008; Rodig et al., 2012). T cells specific for MCPyV
oncoproteins are present in the blood and tumors of patients
with MCC and these patients have levels of circulating
antibodies specific for MCPyV oncoproteins that fluctuate
with disease activity (Paulson et al., 2010; Iyer et al., 2011).
However, these immune responses are insufficient in most
cases to control growth of the cancer, suggesting that MCC
tumors have potent immune evasion strategies.
This report details our studies of the local tumor micro-
environment in MCC tumors. We find these tumors contain
T cells capable of restraining tumor growth but that their
activation is suppressed. We present findings that tumor-
resident regulatory T cells and T-cell exhaustion may be two
strategies used by MCC to evade immune destruction.
RESULTS
MCCs are infiltrated by a mixed population of skin-homing
effector memory, central memory, and regulatory T cells
Immunostaining of MCC cryosections demonstrated the pre-
sence of tumor-infiltrating lymphocytes (TILs) in MCC
(Figure 1a), which in some cases infiltrated into tumor nests
(Figure 1b). In other tumors, T cells surrounded the tumor but
did not penetrate into it, similar to the peritumoral pattern
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Figure 1. Merkel cell carcinomas (MCCs) are infiltrated by a mixed population of effector memory, central memory, and regulatory T cells. (a) MCC cryosection
immunostained for T cells (aCD3, red) and MCC tumor cells (aCD56, green) demonstrates numerous infiltrating T cells. (b) Higher power view shows T cells
infiltrating within tumor nests. (c) In some tumors, T cells were located in a peritumoral distribution. (d) Short-term cultures of MCC tumors allowed isolation
of both T cells and tumor cells. The presence of T cells was studied by direct T-cell isolation or immunostaining in 12 primary MCC tumors and 3 metastatic
lesions. (e) In eight out of eight MCCs, tumor-infiltrating lymphocytes were CD45ROþ memory T cells with both CD4þ and CD8þ T cells. (f) MCC tumors had
varied recruitment of cutaneous lymphocyte antigenþ (CLAþ ) skin-homing T cells. The percentage of CLAþ T cells in normal skin (Nml skin), MCC, and
squamous cell carcinoma (SCC) are shown. A subset of MCC was infiltrated by CLAþ T cells, whereas a second group of tumors excluded these T cells. The
homing defect in this second subset was as pronounced as that observed in SCC, a tumor known to evade immune responses at least in part by excluding CLAþ
T cells. (g) MCCs were infiltrated by higher percentages of L-selectin/CCR7þ central memory T-cell and (h) FOXP3þ regulatory T cells (Tregs) compared with Nml
skin. All histograms are gated to show CD3þ T cells. FSC-H, forward scatter (height); SSC-A, side scatter (area). Bar¼ 50mm.
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previously described (Figure 1c; Paulson et al., 2011). Cells
isolated from primary MCC tumors (Figure 1d) included both
CD4þ and CD8þ CD45ROþ memory T cells (Figure 1e).
Human squamous cell carcinomas of the skin evade
immune responses by excluding cutaneous lymphocyte
antigenþ (CLAþ ) skin-homing effector memory T cells (TEM)
and by recruiting FOXP3þ regulatory T cells (Tregs) with a L-
selectin/CCR7þ central memory T-cell (TCM) phenotype (Clark
et al., 2008). A subset of MCC lacked CLAþ
T cells, suggesting that skin-homing T cells were excluded
(Figure 1f). Immunostaining of MCC tumors demonstrated that
CLA expression correlated with the pattern of T-cell infiltration
into tumors. Three out of three MCCs with higher levels of
T-cell CLA expression were infiltrated by an increased number
of T cells, and T cells were present within the tumor nests
themselves (Figure 1a and b); in contrast, in four out of
four tumors with decreased T-cell CLA expression, the T cells
that surrounded the tumor did not penetrate the tumor,
showing the peritumoral pattern that has been correlated
previously with poor survival (Figure 1c) (Paulson et al.,
2011). However, the presence of CLAþ skin-homing TILs in
tumors was not entirely protective. Of the three patients with
450% CLAþ TILs, only one remained free of disease
following primary excision and local radiotherapy, one
had recurrent disease that responded to combination
chemotherapy and brachytherapy, and one died from
disease. L-selectin/CCR7þ TCM were significantly enhanced
in MCC compared with normal skin, suggesting the preferential
recruitment of TCM to these tumors (Figure 1g). FOXP3
þ Treg
cells were also increased in MCC tumors as compared with
normal skin (Figure 1h) but this did not correlate with
decreased survival. Of the three patients with 420% tumor
Tregs, only one died, one had recurrence that responded to
chemotherapy and brachytherapy, and one remained free of
disease following primary excision and radiotherapy.
T cells infiltrating MCC show decreased activation
CD69 is a marker of early T-cell activation that is expressed by
roughly half of the T cells isolated from noninflamed human
tissues including the skin and gut (Bos et al., 1987; Kunkel et al.,
2002; Clark et al., 2006a). The CD69 expression of MCC TILs
was much lower than T cells isolated from normal, noninflamed
human skin (Figure 2a and c), suggesting decreased activation.
CD25 is a marker for later stages of T-cell activation that is
expressed by both activated T cells and FOXP3þ Tregs. Normal
human skin contains a significant population of CD25þ
FOXP3--activated T cells and a smaller population of CD25þ
FOXP3þ Tregs (Figure 2b; Clark et al., 2006a). Although
normal numbers of MCC TILs expressed CD25, the vast
majority of these were FOXP3þ Tregs (Figure 2a–c); the
CD25þ FOXP3--activated effector T cells present in normal
skin were absent. Taken together, these results demonstrate a
marked inhibition of activation in the MCC TILs.
Culture of MCC tumors in IL-2 and IL-15 leads to T-cell
proliferation, activation, and expansion of CD8 T cells
Immunostimulatory cytokines including IL-2 and IL-15 have
been used in vitro to expand TILs with antitumor activity from
malignant melanoma (Mueller et al., 2008; Rosenberg et al.,
2011). We expanded T cells from MCC tumors with IL-2 and
IL-15 for 1 week and observed marked increases in cell size
and granularity, enhanced activation as evidenced by
increased expression of both CD69 and CD25, increased
numbers of CD25þ FOXP3--activated effector T cells, and
reduced percentages of CCR7þ /L-selectinþ TCM (Figure 3a
and b). After 3 weeks of stimulation, we observed T-cell
proliferation, particularly CD8 T cells, as indicated by the
proliferation marker Ki-67 (Figure 3d). In contrast to these
population shifts, we found no changes in the percentages of
CLAþ skin-homing or FOXP3þ Tregs (Figure 3c). Further
studies demonstrated that IL-15 was critical for enhancing
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Figure 2. T cells infiltrating Merkel cell carcinomas (MCCs) show decreased activation. (a) MCC tumor-infiltrating lymphocytes showed markedly reduced
expression of the early activation antigen CD69. (b) Expression of the activation marker CD25 was largely restricted to FOXP3þ regulatory T cells. CD69 and
CD25 expression from two tumors are shown; similar findings were observed in six additional tumors. The CD25þ FOXP3 -activated T-cell population observed
in normal skin was absent from MCC tumors. (c) The mean and SEM of CD69þ and CD25þFOXP3 effector T cells (Teff) from eight MCC tumors are shown,
compared with four samples of normal skin. All histograms are gated to show CD3þ T cells.
M Dowlatshahi et al.
Suppressed Activity of Tumor-Specific T Cells in Human MCC
www.jidonline.org 1881
T-cell activation and proliferation, as these were mostly
unchanged by IL-2 treatment alone (Supplementary Figure
S1 online).
In vitro treatment of MCC tumors with IL-2 and IL-15 enhances
T-cell cytokine production
We next studied T-cell cytokine production in MCC tumors in
the presence or absence of treatment with IL-2 and IL-15. In
one patient, T cells showed markedly enhanced production of
IFN-g and tumor necrosis factor-a (TNF-a) by both CD4 and
CD8 T cells and enhanced CD4 IL-17 production after IL-2/IL-
15 treatment (Supplementary Figure S2a and b online). The
patient was 90 years old at diagnosis with a high-risk, 3-cm
primary lesion and evidence of micrometastases. She was
treated with wide excision and local radiation therapy and
remains well, despite the high-risk nature of her primary
lesion. A second subset of patients demonstrated the increased
production of IFN-g and/or TNF-a but little IL-17 production
(Supplementary Figure S2c online). A third group of patients
showed significant production of T helper 2 cytokines (IL-4, IL-
13) and IL-10 and no enhancement of IFN-g, TNF-a, and IL-17
production after treatment with IL-2/IL-15 (Supplementary
Figure S2d online).
T cells isolated from patient MCC6 at the time of initial
biopsy showed low levels of IFN-g and TNF-a production
even after IL-2/IL-15 treatment. However, T cells isolated from
the same primary tumor 19 days later at the time of full
excision showed enhanced production of IFN-g and TNF-a,
suggesting that the initial biopsy event triggered either migra-
tion of T helper 1 T cells into the tumor or allowed enhanced
cytokine production (Supplementary Figure S2e online).
MCC tumors contain CD8þ FOXP3þ Treg and plasmacytoid
dendritic cell
Classical FOXP3þ Tregs are CD4þ but suppressive CD8þ
FOXP3þ Tregs have been described in human transplant
recipients, mouse models of autoimmune diseases, and the
microenvironments of many tumors (Chang et al., 2002;
Rifa’i et al., 2004; Xystrakis et al., 2004; Yang et al., 2010).
We observed a discrete population of CD8þFOXP3þ T cells
in MCCs that expanded in concert with effector T cells
during IL-2/IL-15 treatment (Figure 4a). These CD8 Tregs
expressed the skin-homing addressin CLA, but lacked CCR4
and had a CCR7 non-TCM phenotype (Figure 4b). The
majority expressed intracellular cytotoxic T-lymphocyte anti-
gen 4 and glucocorticoid-induced TNFR family related gene,
two immunomodulatory molecules also expressed by CD4þ
Tregs (Sakaguchi, 2000), and nearly all expressed high levels
of HLA-DR, a marker for high suppressive capacity in humans
(Baecher-Allan et al., 2006). The expression of HLA-DR,
glucocorticoid-induced TNFR family related gene, and
intracellular cytotoxic T-lymphocyte antigen 4 by T cells
from normal human skin is also included (Supplementary
Figure S3 online). Immunostained tumor cryosections
revealed frequent CD123þ plasmacytoid dendritic cells
(Figure 4c and d), which have been shown to induce
formation of CD8þFOXP3þ Tregs in the tumor microenvir-
onment of ovarian carcinoma (Wei et al., 2005).
TILs in MCC show evidence of T-cell exhaustion
PD-1 expression by TILs in tumors in the presence of PD-1
ligands can indicate T-cell exhaustion (Blank et al., 2006;
Ahmadzadeh et al., 2009; Chapon et al., 2011; Jin et al.,
2011). Despite the low levels of activation observed in MCC
TILs, a significant percentage of both CD4þ and CD8þ TILs
expressed PD-1 (Figure 5a–c). PD-1 expression by TILs
was reduced after treatment of tumors with IL2/IL-15, parti-
cularly among CD8þ T cells (Figure 5b and c). TIL expression
of PD-1 by tumor T cells was significantly higher than that
of T cells from normal skin and blood (Figure 5c). Treatment
of tumors with IL-2 and IL-15 reduced TIL expression of
PD-1 to levels observed in normal skin T cells (Figure 5c). Two
PD-1 ligands, PD-L1 and PD-L2, were present in the tumor
microenvironment but not expressed by the tumor cells
themselves (Figure 6d and e). Instead, they were expressed by
a population of CD11cþ dendritic cells (Figure 5f). In addition,
a small subpopulation of CD163þ macrophages within the
tumor also expressed PD-L1 and PD-L2 (data not shown).
MCC tumors contain tumor-specific T cells capable of
controlling tumor growth
T cells expanded from MCC treated in vitro with IL-2 and IL-15
showed skewing of the TCR repertoire among both CD4þ and
CD8þ T cells, suggesting that expansion may be antigen-
specific (Figure 6a–c). The expansion of T cells and simulta-
neous loss of viable tumor cells suggested that viable tumor cells
may be killed by expanding T cells (Figure 6d). Cytokine-treated
CD8þ TILs showed the upregulation of CD137, a marker of
antigen-specific T-cell activation used to identify melanoma or
virus-specific TIL after in vitro expansion (Figure 6e; Wehler
et al., 2008; Hernandez-Chacon et al., 2011). Significant killing
of tumor cells was observed after culture of autologous tumor
cells with IL-2/IL15 expanded tumor T cells as compared with
that induced by nonexpanded TILs (Figure 6f). A shorter-term
cytotoxicity assay utilizing a fluorogenic caspase substrate also
demonstrated tumor cell killing by expanded TILs, which were
superior to that observed using nonexpanded TILs from the same
tumor (Figure 6g). MCC tumor fragments of 2 mm implanted
subcutaneously into NOD/SCID/IL2-receptor g-chainnull (NSG)
mice failed to grow in size (Figure 6i and j). Hypothesizing that
T cells transferred with the tumor may be preventing tumor
growth, we isolated T cells from tumors 5 days after implanta-
tion into mice. T cells from implanted tumors showed enhanced
activation, as shown by the increased expression of CD69 and
CD25 (Figure 6h). T-cell expression of PD-1 declined, as did the
percentage of FOXP3þ Treg. We treated implanted mice
systemically with denileukin diftitox, a recombinant fusion
protein that selectively depletes human CD25-expressing T
cells, including activated effector and regulatory cells (Ho
et al., 2004; Morse et al., 2008). MCCs implanted into
denileukin diftitox-treated mice grew and could be transferred
to additional animals (Figure 6i and j).
Metastatic lesions of MCC also contain T cells that can be
activated and expanded by treatment with IL-2 and IL-15
Similar to our findings in primary tumors, T cells from IL-2/
IL-15-treated MCC metastases expanded, upregulated the
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Figure 3. Culture of Merkel cell carcinoma (MCC) tumors in IL-2 and IL-15 leads to T-cell activation, proliferation, and expansion of CD8 T cells. (a) T cells from
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n.s., not significant.
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expression of activation markers CD69 and CD25, and CD8
expression of CD137 was upregulated (Supplementary Figure
S4a and b online). There was enhanced IFN-g production and
skewing of the T-cell repertoire and increased percentages of
effector T cells (Supplementary Figure S4c and d online). In
brief, metastatic lesions also contain T cells, and their
activation and cytokine production was enhanced by IL-2/IL-
15 treatment.
DISCUSSION
As with other virally associated cancers, T-cell immunity has a
critical role in the susceptibility and immune responses to
MCC. Incidence is markedly increased in immunosuppressed
individuals and withdrawal of iatrogenic immunosuppression
or biopsy itself has induced regression of MCC (Friedlaender
et al., 2002; Muirhead and Ritchie, 2007; Heath et al., 2008;
Wooff et al., 2010; Val-Bernal et al., 2011). Although most if
not all (Rodig et al., 2012) of MCCs have genomic integration
of MCPyV and produce viral proteins including small and
large T antigens, these tumors are still highly malignant in
immunocompetent individuals (Feng et al., 2008; Foulongne
et al., 2008; Shuda et al., 2008; Becker et al., 2009; Shuda
et al., 2009; Nakamura et al., 2010; Paolini et al., 2011). Of
the MCCs, 92% occur in immunocompetent individuals, and
mortality is 30%, making MCC a more fatal cancer than
malignant melanoma (Heath et al., 2008). The highly
malignant nature of this virally mediated cancer suggests
that MCC has potent strategies for evading immune response
and that neutralization of these strategies may enhance
antitumor immunity.
Cancer destruction requires not only the generation of
tumor-specific T cells but also the ability of these T cells to
access the tumor once they are generated (Gajewski, 2007).
T cells are imprinted with the expression of tissue-specific
addressins and preferentially migrate to the peripheral tissue
in which they first encountered antigen (Campbell and
Butcher, 2002; Kupper and Fuhlbrigge, 2004). MCC-specific
T cells should express the skin-homing addressin CLA because
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Figure 6. MCC tumors contain tumor-specific T cells capable of controlling tumor growth. (a–c) Expansion of tumor-infiltrating lymphocyte by treatment of
tumors with IL-2 and IL-15 led to marked skewing of the T-cell repertoire. Two representative tumors are shown; similar results were observed in three additional
tumors. Tumors were cultured for 3 weeks in IL-2 and IL-15 or control medium. (d) Tumors treated for 3 weeks with IL-2 and IL-15 showed marked expansion of
CD3þ T cells (gray) and loss of viable CD56þ tumor cells (black) from the cultures. (e) CD8þ T cells tumors treated for 3 weeks showed the upregulation of
CD137, a marker of antigen-specific T-cell activation. Representative histograms and the mean and SEM of CD137 expression by nonexpanded and expanded
CD8 T cells from five MCCs are shown. Histograms are gated to show CD8þT cells. (f) Death of autologous tumor cells was observed after coculture with
autologous expanded T cells from IL-2- and IL-15-treated tumors and was greater than that observed after coculture with nonexpanded T cells from the same
tumors. (g) A short-term cytotoxicity assay measuring caspase activation demonstrated cytotoxic killing of autologous tumor cells by T cells isolated from IL-2- and
IL-15-treated tumors. The ratios of T cells/tumor cells are shown. (h) T cells isolated from MCC before (D0) and 5 days after (D5) subcutaneous implantation into
immunodeficient mice showed increased expression of activation antigens CD69 and CD25, reduced percentages of FOXP3þ regulatory T cell, and reduced the
expression of PD-1. (i) MCC tumors implanted subcutaneously into immunodeficient mice did not grow unless activated T cells transferred with the graft were
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(area); TIL, tumor-infiltrating lymphocyte. Scale of ruler shown¼ 1 mm/division.
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MCC are cutaneous tumors and T cells will have first
encountered antigen within the skin-draining lymph nodes.
We observed decreased numbers of skin-homing CLAþ T
cells in a subset of MCCs, suggesting the presence of a T-cell
homing defect in at least some tumors. Impaired T-cell
homing as a result of decreased vascular addressin
expression has been reported in a number of human
cancers, including malignant melanoma, cutaneous
squamous cell carcinoma, breast, gastric, cervical, and lung
cancers (Piali et al., 1995; Madhavan et al., 2002; Weishaupt
et al., 2007; Clark et al., 2008; Trimble et al., 2010). Indeed,
prior studies have shown that the presence of CD8 T cells
within the MCC tumor itself is correlated with better patient
outcomes (Paulson et al., 2011). However, patients with
tumors that showed infiltration with CLAþ skin-homing T
cells did not have a markedly improved survival, suggesting
that other immunosuppressive mechanisms were also at work.
Our results suggested that at least some MCC tumors
contained tumor-specific T cells but that the activation of
these T cells was markedly suppressed. The expression of the
activation markers CD69 and CD25 was severely decreased in
MCC TILs, even lower than the T cells from normal, non-
inflamed human skin (Figure 2). In vitro culture of MCC with
the T-cell activating cytokines IL-2 and IL-15 led to the marked
activation and expansion of tumor T cells, loss of viable tumor
cells from cultures, and upregulation of CD137 on CD8 T
cells, a marker of antigen-specific T-cell activation that has
been used to identify melanoma or virus-specific TIL after
in vitro expansion (Figure 6; Wehler et al., 2008; Hernandez-
Chacon et al., 2011). T cells expanded from MCC tumors
killed autologous tumor cells in vitro (Figure 6f and g).
Significantly, MCC tumors implanted subcutaneously into
NSG mice, an immunodeficient mouse strain that lacks
T cells, B cells, and natural killer cells, failed to grow unless
their activated T cells were depleted from the transplanted
tumor by treatment with denileukin diftitox (Figure 6h–j; Ho
et al., 2004; Morse et al., 2008). These experiments suggest
that at least some MCC tumors contain T cells capable of
controlling tumor growth.
These findings suggest that potent mechanisms for the
suppression of T-cell activation exist within the MCC tumor
microenvironment and that intratumoral administration of
T-cell activating agents may be capable of stimulating TILs,
thereby enhancing immune responses. Indeed, intratumoral
injection of IFN-b was recently reported to induce MCC
regression in four patients (Paulson et al., 2011). We found
that the combination of IL-2 and IL-15 was critical for the
expansion and activation of MCC TILs. Surprisingly, IL-2 alone
had little effect on proliferation and cytokine production of
MCC TILs (Supplementary Figure S1 online), whereas IL-15
alone enhanced cytokine production but resulted in less
proliferation (data not shown). Both IL-2 and IL-15 induce
antigen-independent proliferation of T cells and participate in
bystander T-cell proliferation during immune responses
(Lodolce et al., 2001). Under normal conditions, IL-2 has a
crucial role in sustaining Tregs and maintaining peripheral
tolerance, whereas IL-15 controls the survival and turnover of
memory T cells (Sprent et al., 2008). In a mouse model of
adoptive immunotherapy for melanoma, T cells expanded
in vitro with IL-15 were longer lived and more effective in vivo
than those generated with IL-2 (Mueller et al., 2008). Our
results suggest intratumoral therapy with potent activators of
T-cell function, including the combination of IL-2 and IL-15,
may be effective in enhancing local antitumor immunity.
Our studies have identified Treg inhibition and T-cell
exhaustion as two possible mechanisms for the inhibition of
T-cell activity we observe in MCC. MCC contained increased
numbers of both CD4 and CD8 Tregs (Figures 1 and 4). CD8
Tregs contribute to disease progression in prostate and color-
ectal cancer and have also been described in ovarian cancer
and malignant melanoma (Wei et al., 2005; Kiniwa et al.,
2007; Chaput et al., 2009; ; Kaufman et al., 2010). CD8 Tregs
were more efficient than CD4 Tregs in reducing CD4 T-cell
proliferation and T helper 1 cytokine production (Filaci et al.,
2011). MCCs are also heavily infiltrated by plasmacytoid
dendritic cell, a cell type known to induce the formation of
CD8 Tregs (Wei et al., 2005). Our results suggest that
therapies that inhibit Treg activity, such as ipilimumab, may
be useful in MCC.
PD-1 was expressed on approximately half of MCC T cells,
despite their markedly suppressed activation status. PD-1, a
CD28/cytotoxic T-lymphocyte antigen 4 family member, is
expressed by activated T cells but when expressed in tumors
in the presence of its ligands PD-L1 or PD-L2, it can be a sign
of T-cell exhaustion (Jin et al., 2011). PD-1 is upregulated on T
cells in malignant melanoma (Blank et al., 2006; Chapon
et al., 2011), and increased PD-1 expression correlates with an
exhausted phenotype and impaired effector function
(Ahmadzadeh et al., 2009). MCC TILs showed markedly
suppressed activation, and therefore PD-1 expression was
unlikely to be the result of T-cell activation and more likely
reflected T-cell exhaustion. The activation and expansion of
TILs with IL-2 and IL-15 led to marked decreases in TIL PD-1
expression along with potent enhancement of cytokine
production and antitumor cytotoxicity, consistent with
recovery from the exhausted phenotype (Figures 5, 6 and
Supplementary Figure S2 online). We observed a population
of dendritic cells and macrophages within MCCs that
expressed PD-L1 and PD-L2 and may be responsible for the
induction of PD-1 on tumor T cells. These findings suggest that
medications such as MDX-1106 that target the PD-1 pathway
may have a role in the treatment of patients with MCC
(Brahmer et al., 2010).
MCCs are virally associated cancers that should be emi-
nently recognizable by the immune system. The fact that
MCCs are highly malignant in immunocompetent individuals
suggests they must have formidable strategies for evading
immune responses. We found that MCC tumors utilize a
spectrum of immune evasion strategies, including impairment
of T-cell homing and local suppression of T-cell activation.
Impaired T-cell activation likely results at least in part from
locally high concentrations of both CD4 and CD8 Tregs
and the expression of PD-L1 and PD-L2 within the tumor
microenvironment, leading to T-cell exhaustion. Our work
suggests that adjuvant therapy of high-risk patients with agents
that stimulate T-cell activity, block Treg function, and inhibit
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PD-1 signaling may enhance antitumor immunity in patients
with MCC.
MATERIALS AND METHODS
Patient samples
MCC tumors and squamous cell carcinomas were obtained from the
Department of Dermatology at Brigham and Women’s Hospital, the
Cutaneous Oncology Program at the Dana-Farber/Brigham and
Women’s Cancer Center, and the Fred Hutchinson Cancer Research
Center, University of Washington. Acquisition of tumor samples and
all studies were approved by the Institutional Review Board of the
Dana-Farber Cancer Institute/Harvard Cancer Center and were
performed in accordance with the Declaration of Helsinki Principles.
Written informed consent was received from participants before
inclusion in the study. Twelve primary tumors and three metastases
were studied. Six out of six tumors studied tested positive for the
presence of the MCPyV, four by reverse transcriptase–PCR, and two
by immunohistochemical staining for large T antigen as recently
described (data not shown; Rodig et al., 2012). Normal human skin
was obtained as discarded tissues following plastic surgery
procedures.
Isolation of T cells from MCC tumors and normal skin
T cells were isolated from normal skin, biopsy-proven MCC tumors,
and squamous cell carcinoma tumors as previously described
(Clark et al., 2006b).
Flow cytometry studies
Flow cytometry analysis of T cells was performed using directly
conjugated monoclonal antibodies from: BD Biosciences (San Jose,
CA) (CD3, CD4, CD8, CD25, CD69, CD45RO, CD45RA, CD56, and
CD137), BD PharMingen (San Diego, CA) (CLA, CD73), Abcam
(Cambridge, MA) (CD39), Beckman Coulter (Hebron, KY) (L-selectin),
R&D Systems (Minneapolis, MN) (CCR7), and eBioscience (San
Diego, CA) (FOXP3, clone PCH101). IOtest Beta Mark kit (Beckman
Coulter) was used for TCR repertoire analysis. For cytokine produc-
tion analysis, T cells from MCC tumors were stimulated with either
control medium or 50 ng ml 1 phorbol 12-myristate 13-acetate and
750 ng ml 1 ionomycin for 6 h, with 10mg ml 1 Brefeldin-A (Cal-
biochem, Chicago, IL) added after 1 hour. Cells were stained for
surface markers, fixed, permeabilized, and stained with directly
conjugated anti-cytokine antibodies. Analysis of flow cytometry
samples was performed on Becton Dickinson FACScan or FACSCanto
instruments (Becton Dickinson, San Jose, CA), and data were
analyzed using FACSDiva software (V5.1) (BD Biosciences).
Immunofluorescence studies
MCC tumors were embedded in optimal cutting temperature, frozen,
and stored at  80 1C. Five micrometer cryosections were cut, air
dried, fixed in acetone, rehydrated in phosphate-buffered saline, and
blocked with 20mg ml 1 of human IgG (15 minutes, Jackson Immu-
noResearch Laboratories, West Grove, PA). Sections were incubated
with primary antibody (30 minutes), followed by three rinses in
phosphate-buffered saline/1% BSA. If necessary, secondary antibody
was added (1:100 dilution, 30 minutes), followed by three rinses.
Sections were mounted using Prolong Gold anti-fade mounting
medium with 40,6-diamidino-2-phenylindole (Invitrogen, Carlsbad,
CA) and examined by a microscope (Eclipse 6600; Nikon, Melville,
NY) equipped with a ( 40/0.75) objective lens (Plan Fluor; Nikon).
Images were captured with a camera (SPOT RT model 2.3.1;
Diagnostic Instruments, Sterling Heights, MI) and acquired with SPOT
[4.0.9] software (Diagnostic Instruments). Antibodies from: BD
Biosciences (CD3, PD-1, PD-L1, PD-L2, HLA-DR), Abcam (CD163),
R&D Systems (CD11c), and Biolegend (CD56, clone HCD56).
Cell viability and cytotoxicity studies
Autologous tumor cells present in explant cultures were cocultured
with non-expanded or expanded T cells from 3-week explant cultures
and tumor cell viability was assessed by flow cytometry after 18 hours
by cell scatter and/or exclusion of 7-AAD viability stain (BD
Biosciences). A second, shorter-term cytotoxicity assay was per-
formed by incubating autologous T cells at the indicated T cell-to-
tumor cell ratio for 2 hours in the presence of a fluorogenic caspase
substrate; cytotoxic tumor cell death was assayed by flow cytometry
as per manufacturer’s instructions (CyToxiLux Kit, OncoImmunin,
Gaithersburg, MD).
Mice xenografted with MCC tumors
Freshly excised MCC tumors were divided into four equal portions
at least 3 mm in each dimension and implanted subcutaneously
on the dorsal flank of NOD/SCID/IL2-receptor g-chainnull mice
(Jackson Laboratories). Mice received 50ml intraperitoneal injections
on days 0, 2, 6, 7, and 9 of either saline or denileukin diftitox
(7.2 mcg ml 1). Tumor size was monitored by palpation for 8 weeks,
at which point they were harvested and measured. The Harvard
Medical Area Standing Committee on Animals approved all described
studies.
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